Literature DB >> 3666042

Dissociation of actions of BRL 34915 in the rat portal vein.

S S Shetty1, G B Weiss.   

Abstract

In rat portal vein, 0.5 and 5.0 microM BRL 34915 [(+/-)-6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-1-pyrrolidyl++ +)-2H- benzo[b]pyran-3-ol] abolished spontaneous rhythmic movements and norepinephrine (NE)-induced tension responses, respectively. Only the higher (5 microM) concentration of BRL 34915 increased 42K efflux and inhibited the NE-induced increase in 42K efflux. These results suggest that BRL 34915 inhibits spontaneous rhythmic movements and NE-induced tension responses by differing mechanisms of action and that only the block of the NE-induced tension response is related to K+ permeability or conductance changes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3666042     DOI: 10.1016/0014-2999(87)90570-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  The effects of cromakalim on ATP-sensitive potassium channels in insulin-secreting cells.

Authors:  M J Dunne; R J Aspinall; O H Petersen
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

2.  Action of cromakalim on potassium membrane conductance in isolated heart myocytes of frog.

Authors:  R Pilsudski; O Rougier; Y Tourneur
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

3.  BRL 34915 (cromakalim) activates ATP-sensitive K+ current in cardiac muscle.

Authors:  M C Sanguinetti; A L Scott; G J Zingaro; P K Siegl
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Actions of BRL 34915 (Cromakalim) upon convulsive discharges in guinea pig hippocampal slices.

Authors:  C Alzheimer; G ten Bruggencate
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-04       Impact factor: 3.000

5.  Comparison of the effluxes of 42K+ and 86Rb+ elicited by cromakalim (BRL 34915) in tonic and phasic vascular tissue.

Authors:  U Quast; Y Baumlin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

6.  Differences between the effects of cromakalim and nifedipine on agonist-induced responses in rabbit aorta.

Authors:  K M Bray; A H Weston; S Duty; D T Newgreen; J Longmore; G Edwards; T J Brown
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

7.  Comparative study of the effects of cromakalim (BRL 34915) and diazoxide on membrane potential, [Ca2+]i and ATP-sensitive potassium currents in insulin-secreting cells.

Authors:  M J Dunne; D I Yule; D V Gallacher; O H Petersen
Journal:  J Membr Biol       Date:  1990-03       Impact factor: 1.843

8.  Effects of cromakalim on the contraction and the membrane potential of the circular smooth muscle of guinea-pig stomach.

Authors:  K Ito; T Kanno; K Suzuki; K Masuzawa-Ito; T Takewaki; H Ohashi; M Asano; H Suzuki
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

9.  Modulation of intracellular calcium by potassium channel openers in vascular muscle.

Authors:  P Erne; K Hermsmeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

10.  Cromakalim inhibits electrically-evoked [3H]acetylcholine release from a tube-preparation of the rat isolated trachea by an epithelium-dependent mechanism.

Authors:  I Wessler; C Hölz; J Maclagan; D Pohan; T Reinheimer; K Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.